CM
ARQT icon

Caption Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Caption Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80,000
Closed -$1.11M – 1503
2024
Q4 		$1.11M Sell
80,000
-25,000
-24% -$274K 0.01% 882
2024
Q3 		$977K Buy
105,000
+30,700
+41% +$303K 0.02% 782
2024
Q2 		$691K Buy
+74,300
New +$672K 0.01% 748
2023
Q3 		– Sell
-135,000
Closed -$1.29M – 1261
2023
Q2 		$1.29M Buy
135,000
+65,000
+93% +$721K 0.02% 605
2023
Q1 		$770K Sell
70,000
-206,000
-75% -$2.98M 0.01% 686
2022
Q4 		$4.08M Buy
276,000
+211,000
+325% +$3.69M 0.06% 356
2022
Q3 		$1.24M Buy
+65,000
New +$1.47M 0.02% 795
2022
Q1 		– Sell
-18,500
Closed -$384K – 1442
2021
Q4 		$384K Buy
+18,500
New +$368K ﹤0.01% 1309

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's ARQT Position: Q2 2024 in Review

Caption Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 79,500 shares — an estimated $719K sold.

Caption Management first reported a position in ARQT in Q2 2022 and held it in 2 quarters. The position peaked at $788K in Q1 2024. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Caption Management reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Caption Management sold 79,500 Arcutis Biotherapeutics shares in Q2 2024, an estimated $719K.
  • Caption Management first reported a position in Arcutis Biotherapeutics in Q2 2022 and held it in 2 quarters.
  • Caption Management's Arcutis Biotherapeutics position peaked at $788K in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Caption Management's 13F filing for Q2 2024, filed 14 Aug 2024.